From Medscape Oncology

Coverage from the

Genitourinary Cancers Symposium (GUCS) 2021

February 11 - 13, 2021; Virtual/Online

February 11 - 13, 2021 Virtual/Online
  • GUCS 2021 Combo Shows 'Impressive' Survival Results in First-Line RCC The combination of lenvatinib and pembrolizumab outperformed sunitinib as first-line therapy for advanced clear-cell renal cell carcinoma (RCC) in the CLEAR trial.
  • GUCS 2021 Cabozantinib Could Be New Standard for Papillary RCC Cabozantinib outperforms the current standard of care for renal cell carcinoma (RCC), according to results from the Southwest Oncology Group 1500 trial.
  • GUCS 2021 'Attractive' Option for Early Metastatic Seminoma For early-stage seminoma that metastasizes to one or two retroperitoneal lymph nodes, surgical excision is an "attractive" alternative, according to an investigator from the phase 2 SEMS trial.

Conference News

Medscape Oncology© WebMD, LLC

Any views expressed above are the author's own and do not necessarily reflect the views of WebMD or Medscape.

Popular News from GUCS 2020

Previous Coverage